BRAF and neoplasm: The univariate analyses demonstrated a significant association between the presence of BRAF-V600E and tumor size (P<0.001), multifocality (P=0.036), histology (P<0.001), RAI dose (P<0.001), follow-up time (P=0.001) and recurrence risk stage (P<0.001), whereas there was no significant association with age, sex, ethnicity, lymphocytic thyroiditis, lymph node positivity, ETE, residual tumor, RAI treatment, recurrence, TNM stage and AJCC stage (Table I).